,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,11230 Sorrento Valley Road,Suite 220,San Diego,CA,92121,United States,858 414 1477,https://genebiotherapeutics.com,Biotechnology,Healthcare,"Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",3,"{'maxAge': 1, 'name': 'Mr. Christopher J. Reinhard', 'age': 68, 'title': 'Co-Founder, CEO, Pres, Treasurer & Director', 'yearBorn': 1954, 'fiscalYear': 2020, 'totalPay': 240000, 'exercisedValue': 0, 'unexercisedValue': 0}",1609372800,86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,0.0,-19.483747,20,20,0,0,0,0.0,0.0,0,0,64,1e-06,0.0001,0.0001,0.0001,0.0,0.0,USD,181520,0.0,60791182,64931900,150251,448453,1385683200,1388448000,0.0171,0.063769996,0.0,1.03,0.0178,-0.096,1609372800,1640908800,1609372800,-517897,-0.02,1:20,1374105600,-0.144,PNK,EQUITY,CRXM,CRXM,TAXUS CARDIUM PHARMACEUTICALS G,"Gene Biotherapeutics, Inc.",957360600,America/New_York,EDT,-14400000,1e-06,none,386027,0.006,-1260365,1260469,0.077,0.082,-2.619,-707668,-1133005,0.0,0.0,0.0,USD,
1,11230 Sorrento Valley Road,Suite 220,San Diego,CA,92121,United States,858 414 1477,https://genebiotherapeutics.com,Biotechnology,Healthcare,"Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",3,"{'maxAge': 1, 'name': 'Mr. James L. Grainer', 'age': 67, 'title': 'Chairman, CFO & Sec.', 'yearBorn': 1955, 'exercisedValue': 0, 'unexercisedValue': 0}",1609372800,86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,0.0,-19.483747,20,20,0,0,0,0.0,0.0,0,0,64,1e-06,0.0001,0.0001,0.0001,0.0,0.0,USD,181520,0.0,60791182,64931900,150251,448453,1385683200,1388448000,0.0171,0.063769996,0.0,1.03,0.0178,-0.096,1609372800,1640908800,1609372800,-517897,-0.02,1:20,1374105600,-0.144,PNK,EQUITY,CRXM,CRXM,TAXUS CARDIUM PHARMACEUTICALS G,"Gene Biotherapeutics, Inc.",957360600,America/New_York,EDT,-14400000,1e-06,none,386027,0.006,-1260365,1260469,0.077,0.082,-2.619,-707668,-1133005,0.0,0.0,0.0,USD,
2,11230 Sorrento Valley Road,Suite 220,San Diego,CA,92121,United States,858 414 1477,https://genebiotherapeutics.com,Biotechnology,Healthcare,"Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",3,"{'maxAge': 1, 'name': 'Dr. Lois A. Chandler', 'age': 64, 'title': 'Chief Operating Officer', 'yearBorn': 1958, 'exercisedValue': 0, 'unexercisedValue': 0}",1609372800,86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,0.0,-19.483747,20,20,0,0,0,0.0,0.0,0,0,64,1e-06,0.0001,0.0001,0.0001,0.0,0.0,USD,181520,0.0,60791182,64931900,150251,448453,1385683200,1388448000,0.0171,0.063769996,0.0,1.03,0.0178,-0.096,1609372800,1640908800,1609372800,-517897,-0.02,1:20,1374105600,-0.144,PNK,EQUITY,CRXM,CRXM,TAXUS CARDIUM PHARMACEUTICALS G,"Gene Biotherapeutics, Inc.",957360600,America/New_York,EDT,-14400000,1e-06,none,386027,0.006,-1260365,1260469,0.077,0.082,-2.619,-707668,-1133005,0.0,0.0,0.0,USD,
3,11230 Sorrento Valley Road,Suite 220,San Diego,CA,92121,United States,858 414 1477,https://genebiotherapeutics.com,Biotechnology,Healthcare,"Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",3,"{'maxAge': 1, 'name': 'Dr. Ronald J. Shebuski', 'age': 69, 'title': 'Chief Scientific Officer', 'yearBorn': 1953, 'exercisedValue': 0, 'unexercisedValue': 0}",1609372800,86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,0.0,-19.483747,20,20,0,0,0,0.0,0.0,0,0,64,1e-06,0.0001,0.0001,0.0001,0.0,0.0,USD,181520,0.0,60791182,64931900,150251,448453,1385683200,1388448000,0.0171,0.063769996,0.0,1.03,0.0178,-0.096,1609372800,1640908800,1609372800,-517897,-0.02,1:20,1374105600,-0.144,PNK,EQUITY,CRXM,CRXM,TAXUS CARDIUM PHARMACEUTICALS G,"Gene Biotherapeutics, Inc.",957360600,America/New_York,EDT,-14400000,1e-06,none,386027,0.006,-1260365,1260469,0.077,0.082,-2.619,-707668,-1133005,0.0,0.0,0.0,USD,
4,11230 Sorrento Valley Road,Suite 220,San Diego,CA,92121,United States,858 414 1477,https://genebiotherapeutics.com,Biotechnology,Healthcare,"Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.",3,"{'maxAge': 1, 'name': 'Mr. Duane  Linstrom', 'title': 'Gen. Counsel', 'fiscalYear': 2016, 'exercisedValue': 0, 'unexercisedValue': 0}",1609372800,86400,4,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,1e-06,0.0,-19.483747,20,20,0,0,0,0.0,0.0,0,0,64,1e-06,0.0001,0.0001,0.0001,0.0,0.0,USD,181520,0.0,60791182,64931900,150251,448453,1385683200,1388448000,0.0171,0.063769996,0.0,1.03,0.0178,-0.096,1609372800,1640908800,1609372800,-517897,-0.02,1:20,1374105600,-0.144,PNK,EQUITY,CRXM,CRXM,TAXUS CARDIUM PHARMACEUTICALS G,"Gene Biotherapeutics, Inc.",957360600,America/New_York,EDT,-14400000,1e-06,none,386027,0.006,-1260365,1260469,0.077,0.082,-2.619,-707668,-1133005,0.0,0.0,0.0,USD,
